trending Market Intelligence /marketintelligence/en/news-insights/trending/2NaDqjDqSrtGxIo9cA5soA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Blackstone funds to buy Japan's AYUMI Pharmaceutical

StreetTalk – Episode 69: Banks left with pockets full of cash and few places to go

Street Talk – Episode 69: Banks left with pockets full of cash and few places to go

Street Talk Episode 68 - As many investors zig away from bank stocks, 2 vets in the space zag toward them

Street Talk Episode 66 - Community banks tap the debt markets while the getting is good


Blackstone funds to buy Japan's AYUMI Pharmaceutical

Private equity funds managed by Blackstone Group LP agreed to purchase Japanese pharmaceutical company AYUMI Pharmaceutical Corp., marking the firm's first control private equity investment in the country.

The agreement was reached with local private equity firm Unison Capital Inc. and medical information site company M3 Inc.

Terms of the deal, expected to close in the second quarter, were not disclosed.

Bloomberg News earlier reported that Unison was evaluating a potential sale of the anti-rheumatic drug maker for up to US$1 billion.